Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It also has designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Generation 3 or Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
종목 코드 NXL
회사 이름Nexalin Technology Inc
상장일Sep 16, 2022
CEOMr. Mark White
직원 수6
유형Ordinary Share
회계 연도 종료Sep 16
주소1776 Yorktown
도시HOUSTON
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호77056
전화18322600222
웹사이트https://nexalin.com
종목 코드 NXL
상장일Sep 16, 2022
CEOMr. Mark White
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음